AR038947A1 - Suspension oral de sabor agradable y metodo - Google Patents
Suspension oral de sabor agradable y metodoInfo
- Publication number
- AR038947A1 AR038947A1 ARP030100851A ARP030100851A AR038947A1 AR 038947 A1 AR038947 A1 AR 038947A1 AR P030100851 A ARP030100851 A AR P030100851A AR P030100851 A ARP030100851 A AR P030100851A AR 038947 A1 AR038947 A1 AR 038947A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- bitter taste
- water
- taste
- dry powder
- Prior art date
Links
- 229940100692 oral suspension Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000796 flavoring agent Substances 0.000 title 1
- 235000019634 flavors Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 11
- 229940079593 drug Drugs 0.000 abstract 9
- 235000019658 bitter taste Nutrition 0.000 abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000000843 powder Substances 0.000 abstract 4
- 239000002244 precipitate Substances 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
- 238000011065 in-situ storage Methods 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 235000019640 taste Nutrition 0.000 abstract 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010013911 Dysgeusia Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960003405 ciprofloxacin Drugs 0.000 abstract 1
- KCUWTKOTPIUBRI-VICXVTCVSA-M cloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl KCUWTKOTPIUBRI-VICXVTCVSA-M 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 abstract 1
- 229950004274 ifetroban Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
- 229960001180 norfloxacin Drugs 0.000 abstract 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 abstract 1
- 229960001699 ofloxacin Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación de fármaco en forma de un polvo seco el cual cuando se mezcla con agua, forma una suspensión oral con sabor agradable, substancialmente libre de un sabor amargo, el polvo seco se forma de un fármaco preferiblemente des-quinolona que en solución tiene un sabor amargo, y un agente modificador del pH que es preferiblemente un material alcalino tal como la L-arginina, en donde al mezclar el polvo seco en agua se provoca que el fármaco tenga la solubilidad reducida o se precipite in situ para formar una suspensión oral de sabor agradable esencialmente libre de sabor amargo. También se proporciona una suspensión oral, métodos para la elaboración de la misma y un método para ocultar el sabor amargo de los fármacos que emplean uno o más agentes modificadores del pH. Reivindicación 1: Una composición farmacéutica en forma de un polvo seco que comprende partículas de un fármaco fácilmente soluble en agua, el cual cuando se solubiliza tiene un sabor amargo, y las partículas se tratan de manera que con al adición de agua a ellas, las partículas se hacen menos solubles o forman un precipitado in situ suspendido en el agua y está esencialmente libre de un sabor amargo, en donde el fármaco se hace libre del sabor amargo sin el uso o necesidad de un polímero o recubrimiento en cera o microencapsulación. Reivindicación 9: La composición farmacéutica como se define en la reivindicación 8, en donde el fármaco es un fármaco ácido que forma un precipitado con un agente alcalino modificador del pH o el fármaco es un fármaco básico que forma un precipitado con un agente modificador del pH ácido. Reivindicación 10: La composición farmacéutica como se define en la reivindicación 9, en donde el fármaco ácido es desquinolona, norfloxacino, ciprofloxacino u ofloxacino, y el fármaco básico es monohidratado de cloxacilin de sodio, monohidrato de dicloxicilin de sodio o ifetroban de sodio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36370402P | 2002-03-12 | 2002-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038947A1 true AR038947A1 (es) | 2005-02-02 |
Family
ID=28041802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100851A AR038947A1 (es) | 2002-03-12 | 2003-03-12 | Suspension oral de sabor agradable y metodo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7175856B2 (es) |
| EP (1) | EP1482789A4 (es) |
| JP (1) | JP4619658B2 (es) |
| CN (1) | CN100337630C (es) |
| AR (1) | AR038947A1 (es) |
| AU (1) | AU2003220058B2 (es) |
| BR (1) | BR0308343A (es) |
| CA (1) | CA2478411C (es) |
| MX (1) | MXPA04008720A (es) |
| NO (1) | NO20043986L (es) |
| NZ (1) | NZ534746A (es) |
| PE (1) | PE20030885A1 (es) |
| PL (1) | PL212421B1 (es) |
| TW (1) | TW200304832A (es) |
| WO (1) | WO2003077842A2 (es) |
| ZA (1) | ZA200406585B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005023193D1 (de) * | 2004-10-15 | 2010-10-07 | Suedzucker Ag | Verbessertes trommelcoating-verfahren |
| US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
| CN102964296B (zh) | 2007-03-28 | 2015-03-25 | 阿普泰克斯科技公司 | 去铁酮的氟化衍生物 |
| US20100210604A1 (en) | 2007-06-13 | 2010-08-19 | Meythaler Jay M | Zwitterion solution for low-volume therapeutic delivery |
| US20110021469A1 (en) * | 2007-06-13 | 2011-01-27 | Meythaler Jay M | baclofen solution for low-volume therapeutic delivery |
| JP5009707B2 (ja) * | 2007-07-10 | 2012-08-22 | 東和薬品株式会社 | 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤 |
| US7884227B2 (en) * | 2007-10-26 | 2011-02-08 | Navinta Llc | Felbamate with improved bulk density |
| GB2470494B (en) * | 2008-01-17 | 2012-08-08 | Univ Holy Ghost Duquesne | Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS |
| CN102014904B (zh) * | 2008-04-25 | 2013-02-06 | 阿普泰克斯科技公司 | 具有适口味道的去铁酮液体配制品 |
| ES2351643B1 (es) * | 2009-07-27 | 2011-09-15 | Laboratorio Jaer,S.A. | Utilización de xilitol o sus derivados para el enmascaramiento gustativo de quimioterápicos del grupo del ácido quinolon-o-naftiridoncarboxílico administrados en alimentos destinados a ganado porcino. |
| EP2343089A4 (en) | 2008-09-23 | 2013-05-01 | Jaer S A Lab | USE OF XYLITOL OR DERIVATIVES THEREOF FOR MASKING THE TASTE OF CHEMOTHERAPEUTIC MEDICAMENTS OF THE CHINOLO-N-NAPHTHYRIDONE-CARBOXYLIC ACID GROUP FOR PIG DICULTINATION |
| ES2335334B1 (es) * | 2008-09-23 | 2011-02-09 | Laboratorio Jaer, S.A. | Utilizacion del xilitol para el enmascaramiento gustativo de amargantes en alimentos para animales. |
| WO2011000104A1 (en) | 2009-07-03 | 2011-01-06 | Apotex Technologies Inc. | Fluorinated derivatives of 3-hydroxypyridin-4-ones |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| US20110236494A1 (en) * | 2010-03-04 | 2011-09-29 | Ranbaxy Laboratories Limited | Ciprofloxacin oral suspension |
| GB201006218D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
| CN102397552B (zh) * | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| LT3524595T (lt) | 2014-08-28 | 2022-09-26 | Eisai R&D Management Co., Ltd. | Aukšto grynumo chinolino darinys ir jo gamybos būdas |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| US11648202B2 (en) * | 2017-10-13 | 2023-05-16 | Research Triangle Institute | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof |
| CN110151704A (zh) * | 2019-07-05 | 2019-08-23 | 华裕(无锡)制药有限公司 | 阿奇霉素干混悬剂的制备方法 |
| WO2025043236A1 (en) * | 2023-08-24 | 2025-02-27 | Joseph Fuisz | Edible oral films, compositions, method of manufacture and packaging systems |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8103843L (sv) | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
| CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
| JPS61180771A (ja) * | 1985-01-05 | 1986-08-13 | バイエル・アクチエンゲゼルシヤフト | 安定な抗バクテリア剤水溶液 |
| GB8623557D0 (en) * | 1986-10-01 | 1986-11-05 | Boots Co Plc | Therapeutic agents |
| NL193682C (nl) | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| DE3719764A1 (de) * | 1987-06-13 | 1988-12-22 | Bayer Ag | Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung |
| DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
| DE3831514A1 (de) * | 1988-09-16 | 1990-03-22 | Bayer Ag | Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren |
| US4975465A (en) * | 1989-03-28 | 1990-12-04 | American Home Products Corporation | Orally administrable ibuprofen compositions |
| US5262179A (en) * | 1989-09-13 | 1993-11-16 | Nicholas Kiwi Pty Ltd. | Non-effervescent ibuprofen compositions |
| IE63986B1 (en) * | 1989-12-30 | 1995-06-28 | Akzo Nv | Pharmaceutical preparation for oral administration in fluid form |
| IT1246383B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| JP3184239B2 (ja) * | 1991-04-25 | 2001-07-09 | 京都薬品工業株式会社 | 矯味経口用医薬組成物 |
| DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
| US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| JPH05309314A (ja) | 1992-05-07 | 1993-11-22 | Sumitomo Pharmaceut Co Ltd | コーティング方法 |
| ZA945944B (en) | 1993-08-13 | 1996-02-08 | Eurand America Inc | Procedure for encapsulating nsaids |
| NZ290946A (en) * | 1994-08-12 | 1997-12-19 | Toyama Chemical Co Ltd | Quinolone- or naphthyridone-carboxylic acid derivatives |
| AU689663B2 (en) * | 1994-10-14 | 1998-04-02 | Janssen Pharmaceutica N.V. | Sabeluzole oral suspensions |
| GB9421837D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
| ZA961018B (en) * | 1995-02-08 | 1997-08-08 | Yamanouchi Europ Bv | Oral dosage-forms containing a beta-lactam antibiotic. |
| US5972379A (en) | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
| CN1100053C (zh) * | 1996-02-09 | 2003-01-29 | 富山化学工业株式会社 | 喹诺酮羧酸衍生物或它们的盐类 |
| AUPN969796A0 (en) * | 1996-05-07 | 1996-05-30 | F.H. Faulding & Co. Limited | Taste masked liquid suspensions |
| JP3424038B2 (ja) * | 1996-06-17 | 2003-07-07 | 株式会社日本点眼薬研究所 | 合成抗菌剤水性組成物 |
| AP1409A (en) * | 1999-05-27 | 2005-06-13 | Pfizer Prod Inc | Ziprasidone suspension. |
| US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
-
2003
- 2003-03-06 BR BRPI0308343-8A patent/BR0308343A/pt not_active IP Right Cessation
- 2003-03-06 CN CNB038058405A patent/CN100337630C/zh not_active Expired - Fee Related
- 2003-03-06 MX MXPA04008720A patent/MXPA04008720A/es active IP Right Grant
- 2003-03-06 PL PL373570A patent/PL212421B1/pl unknown
- 2003-03-06 NZ NZ534746A patent/NZ534746A/en not_active IP Right Cessation
- 2003-03-06 AU AU2003220058A patent/AU2003220058B2/en not_active Ceased
- 2003-03-06 WO PCT/US2003/006855 patent/WO2003077842A2/en not_active Ceased
- 2003-03-06 CA CA2478411A patent/CA2478411C/en not_active Expired - Fee Related
- 2003-03-06 EP EP03716347A patent/EP1482789A4/en not_active Withdrawn
- 2003-03-06 JP JP2003575896A patent/JP4619658B2/ja not_active Expired - Fee Related
- 2003-03-11 US US10/386,199 patent/US7175856B2/en not_active Expired - Fee Related
- 2003-03-11 TW TW092105244A patent/TW200304832A/zh unknown
- 2003-03-12 PE PE2003000249A patent/PE20030885A1/es not_active Application Discontinuation
- 2003-03-12 AR ARP030100851A patent/AR038947A1/es not_active Application Discontinuation
-
2004
- 2004-08-18 ZA ZA2004/06585A patent/ZA200406585B/en unknown
- 2004-09-23 NO NO20043986A patent/NO20043986L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20030885A1 (es) | 2003-10-23 |
| TW200304832A (en) | 2003-10-16 |
| US7175856B2 (en) | 2007-02-13 |
| ZA200406585B (en) | 2005-11-30 |
| CN1642415A (zh) | 2005-07-20 |
| CN100337630C (zh) | 2007-09-19 |
| NO20043986L (no) | 2004-09-23 |
| BR0308343A (pt) | 2006-06-06 |
| CA2478411C (en) | 2010-09-28 |
| WO2003077842A3 (en) | 2004-03-25 |
| MXPA04008720A (es) | 2004-12-06 |
| US20030187019A1 (en) | 2003-10-02 |
| WO2003077842A2 (en) | 2003-09-25 |
| NZ534746A (en) | 2006-06-30 |
| EP1482789A4 (en) | 2010-12-29 |
| EP1482789A2 (en) | 2004-12-08 |
| JP4619658B2 (ja) | 2011-01-26 |
| CA2478411A1 (en) | 2003-09-25 |
| JP2006504620A (ja) | 2006-02-09 |
| PL212421B1 (pl) | 2012-09-28 |
| AU2003220058B2 (en) | 2008-05-01 |
| AU2003220058A1 (en) | 2003-09-29 |
| PL373570A1 (en) | 2005-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038947A1 (es) | Suspension oral de sabor agradable y metodo | |
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| IL161290A0 (en) | Stable composition comprising particles in a frozen aqueous matrix | |
| TR200500745T2 (tr) | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. | |
| ECSP044974A (es) | Formulación de suspensión oral estabilizada | |
| JO3404B1 (ar) | تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين | |
| TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
| HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| UY27273A1 (es) | Solución oral de arilpiprazol | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| DK1587514T3 (da) | Hurtigvirkende farmaceutisk præparat | |
| HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
| ID28510A (id) | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 | |
| WO2005065648A3 (en) | Novel drug compositions and dosage forms of topiramate | |
| NI200600146A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
| FR2846327B1 (fr) | Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant. | |
| BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
| AR043536A1 (es) | Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico | |
| JP2002537246A5 (es) | ||
| EP1634585A4 (en) | MEDICINAL PRODUCTS CONTAINING DELAYED MICROTEIL, PROCESS FOR ITS PREPARATION AND MICROPARTICLE CONTAINING PREPARATION | |
| DE60007074D1 (de) | Sulfatierte phosphatidylinositole, ihre herstellung und verwendung | |
| MA27850A1 (fr) | Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate | |
| ATE390126T1 (de) | Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben | |
| ATE425741T1 (de) | Arzneizubereitung und deren anwendung zur behandlung von erkrankungen des inneren ohres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |